The Herbert Irving Comprehensive Cancer Center (HICCC) was designated as an NCI Cancer Center in 1972 and gained comprehensive status in 1979. The HICCC is a component of Columbia University Medical Center is associated with New York-Presbyterian Hospital (NYPH). During the period 2008-2013, CUMC and NYPH committed over $350 million for i) new research initiatives in basic, clinical and population science; ii) new and expanded facilities for laboratory research and clinical activities; iii) recruitment and program restructuring; and iv) support of the Center's administrative office. A new Director, Stephen G. Emerson M.D., Ph.D. was appointed in 2012 and given: i) authority over new facilities, including the Irving Cancer Research Center (ICRC), a 10-story building dedicated to cancer research, with state-of-the-art laboratories and clinical space in the Herbert Irving Pavilion (HIP); ii) a broad-based recruitment plan, which has already attracted 40 new faculty members to the HICCC; and iii) restructuring and expansion of the shared resources. The structure of the HICCC has been organized to increase cancer focus and interdisciplinary collaboration, and now includes 245 members from 22 Departments and 6 Schools, assigned to two Basic Research programs (Cancer Regulatory Networks and Cancer Genetics & Epigenetics), four Disease-Specific programs (Breast Cancer, Prostate Cancer, Neuro-Oncology and Lymphoid Development & Malignancy), and two Population Science programs (Cancer Epidemiology and Prevention, Control & Disparities). The HICCC administers and supports a total of 15 Shared Resources. During the period 2008-2013, the HICCC research activities have been documented in a total of 3057 publications of which 17% are inter-programmatic and 15% are intra-programmatic. The current NCI funding base is $26M (total direct costs), a 13% increase over the 2007 NCI funding base of $23M (total direct costs). The Center is requesting CCSG support of $2,607,495 (total direct costs) for the initial budget period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA013696-44S1
Application #
9608325
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Lin, Alison J
Project Start
1997-07-04
Project End
2019-06-30
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
44
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Sones, Jennifer L; Merriam, Audrey A; Seffens, Angelina et al. (2018) Angiogenic factor imbalance precedes complement deposition in placentae of the BPH/5 model of preeclampsia. FASEB J 32:2574-2586
Park, Karen Sophia; Xu, Christine L; Cui, Xuan et al. (2018) Reprogramming the metabolome rescues retinal degeneration. Cell Mol Life Sci 75:1559-1566
Mumau, Melanie D; Vanderbeck, Ashley N; Lynch, Elizabeth D et al. (2018) Identification of a Multipotent Progenitor Population in the Spleen That Is Regulated by NR4A1. J Immunol 200:1078-1087
Savage, Thomas M; Shonts, Brittany A; Obradovic, Aleksandar et al. (2018) Early expansion of donor-specific Tregs in tolerant kidney transplant recipients. JCI Insight 3:
Caviglia, Jorge Matias; Yan, Jun; Jang, Myoung-Kuk et al. (2018) MicroRNA-21 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis. Hepatology 67:2414-2429
Jauregui, Ruben; Park, Karen Sophia; Tsang, Stephen H (2018) Two-year progression analysis of RPE65 autosomal dominant retinitis pigmentosa. Ophthalmic Genet 39:544-549
Wu, Wen-Hsuan; Tsai, Yi-Ting; Justus, Sally et al. (2018) CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis Pigmentosa: A Brief Methodology. Methods Mol Biol 1715:191-205
Yen, Bonnie; Fortson, Katherine T; Rothman, Nyanza J et al. (2018) Clonal Bifurcation of Foxp3 Expression Visualized in Thymocytes and T Cells. Immunohorizons 2:119-128
Ishida, Chiaki T; Zhang, Yiru; Bianchetti, Elena et al. (2018) Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma. Clin Cancer Res 24:5392-5406
Jin, Chun-Hui; Li, Yang; Xia, Jinxing et al. (2018) CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion. Am J Hematol 93:786-793

Showing the most recent 10 out of 331 publications